MedTrace Logo

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

NCT06334809 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-06-12

No results posted yet for this study

Summary

400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVI at mpMRI;

Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC);

Cohort C: patients with metastatic castration resistant prostate cancer (mCRPC) progressing on a standard treatment.

Conditions

Sponsors & Collaborators

  • Fondazione del Piemonte per l'Oncologia

    lead OTHER

Principal Investigators

  • Pasquale Rescigno, MD · Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo

  • Sabrina Arena, PhD · Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-09
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06334809 on ClinicalTrials.gov